ABBV vs QCOM: Which Is the Better Buy?

Side-by-side comparison of AbbVie Inc. and QUALCOMM Incorporated — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-04-16.
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C High Quality
VS
QUALCOMM Incorporated · Technology
$134.47
+77.7% upside to fair value
Med Conviction Grade B
QuantHub Verdict
QCOM has more upside to fair value (+77.7%). ABBV trades at a lower forward P/E (14.9x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric ABBV QCOM
Current Price $208.05 $134.47
Fair Value Estimate $217.50 $239.00
Upside to Fair Value +4.5% +77.7%
Market Cap $367.9B $143.6B
Forward P/E 14.9x 26.8x
EV / EBITDA 16.7x
Price / Sales 6.1x 3.2x
Price / FCF 20.9x 11.1x
Revenue Growth YoY +8.6% +8.7%
Gross Margin 83.7% 55.1%
Operating Margin 34.7% 27.1%
Return on Equity -129.24% 21.6%
Dividend Yield 3.2%
FCF Yield 4.78% 9.0%
Analyst Consensus Buy Hold
Investment Thesis
ABBV — AbbVie Inc.
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
QCOM — QUALCOMM Incorporated
Qualcomm Incorporated is a leading semiconductor company specializing in wireless chipsets and IP licensing, with dominant positions in 5G modems via QCT (87% of revenue) and steady QTL royalties. The business excels through a vast patent moat, diversification into automotive and IoT, and robust growth (revenue +13% YoY to $44B in FY2025), but faces risks from Apple modem shifts and China exposur…
Accumulation Zones
Metric ABBV QCOM
Zone Low $163.13 $179.00
Zone High $184.88 $203.00
In Buy Zone? No Yes
← ABBV Research    QCOM Research →    All Research